Clinical Trial Update: FLuoresence Image Guided Surgery With A VEGF-targeted Tracer in Soft-tissue Sarcomas in Humans Approach With Bevacizumab-IRDye 800CW [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a VEGF-targeted tracer (Bevacizumab-IRDye 800CW) used in fluorescence image-guided surgery for soft-tissue sarcoma; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Bevacizumab-IRDye 800CW (Bevacizumab-IRDye 800CW)

Snippet

Sponsor: University Medical Center Groningen | Conditions: Soft Tissue Sarcoma | Phase 1, Phase 2 | Status: COMPLETED